Skip Navigation LinksHome > January 1, 2014 - Volume 65 - Issue 1 > Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected T...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0b013e3182a7a97a
Brief Report: Clinical Science

Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients

Gulick, Roy M. MD, MPH*; Fatkenheuer, Gerd MD; Burnside, Robert MPH; Hardy, W. David MD§; Nelson, Mark R. MA, MBBS, FRCP; Goodrich, James PhD, MD¶,1; Mukwaya, Geoffrey MD#; Portsmouth, Simon MBChB, MD**; Heera, Jayvant R. MD, MFPM

Open Access
Collapse Box

Abstract

Background: Maraviroc is unique among approved antiretroviral drugs in targeting the host-cell chemokine coreceptor type-5 receptor. With its novel mechanism of action, we sought to describe the 5-year safety profile of maraviroc.

Methods: Two large phase 3 studies of maraviroc enrolled HIV-infected treatment-experienced patients and followed them up for 5 or more years. Survival and selected clinical end points were identified and assessed.

Results: A total of 938 enrolled patients received maraviroc-containing regimens. Rates of death and selected clinical events (eg, hepatic failure, malignancy, and myocardial infarction) were low during follow-up.

Conclusions: Maraviroc was generally safe in treatment-experienced participants for >5 years.

© 2014 by Lippincott Williams & Wilkins

Login

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.